AUG 23, 2017 5:39 AM PDT

Jury Awards $417M in Baby Powder Cancer Case

WRITTEN BY: Xuan Pham

A California patient claimed her ovarian cancer was caused by Johnson & Johnson’s baby powder product. She sued, and in a historic ruling, the court ordered the company to fork over a record $417 million in damages.

Image credit: Lucas Jackson / Reuters

The patient is 63-year-old Eva Echeverria who has been faithfully using the baby powder on her body since she was 11. Specifically, she used the powder for feminine hygiene purposes, a practice that Johnson & Johnson (J & J) did not caution against until very recently in 2016. By the time J & J made the warning public, Echeverria had already been battling ovarian cancer for 10 years.

Echeverria believed her terminal ovarian cancer was linked to the prolonged use of the talc powder. And in court, her lawyers alleged that J & J had known about such cancer link for some time, but had failed to warn consumers adequately of the product’s risks.

Meanwhile, J & J countered that the science behind the link between talc powder and ovarian cancer is inconclusive. They also reiterated science that supports the safety of the talc powder.

In the end, the jury agreed with Echeverria, and J & J was ordered to pay $70 million in compensatory damages, and another $347 million in punitive damages. All told, the payout of $417 will be the largest sum that’s been awarded in the string of talcum cases plaguing J & J.

Last year, the company lost three similar cases in Missouri, resulting in a total payout of over $300 million in damages. And in May, in another talc-related lawsuit, the company was ordered to pay $110.5 million to a 62-year-old ovarian cancer patient in Virginia.

But according to Echeverria’s lawyers, the case is not about money; rather, it’s about bringing awareness to a potentially carcinogenic product that most of us have in our houses right now.

“Mrs. Echeverria is dying from this ovarian cancer and she said to me all she wanted to do was to help the other women throughout the whole country who have ovarian cancer for using Johnson & Johnson for 20 and 30 years,” said Mark Robinson, Echeverria’s attorney. “She really didn’t want sympathy. She just wanted to get a message out to help these other women.”

"Johnson & Johnson had many warning bells over a 30 year period but failed to warn the women who were buying its product," he said.

J & J plans to appeal the Echeverria cases and others. "We will appeal today's verdict because we are guided by the science," said Carol Goodrich, spokesperson for Johnson & Johnson Consumer Inc.

Additional sources: BBC

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
FEB 11, 2020
Clinical & Molecular DX
FEB 11, 2020
Portable device turns smartphones into diagnostic labs
Your smartphone lets you connect with friends, stores your memories, sends work emails and pays for your groceries. Soon ...
FEB 15, 2020
Clinical & Molecular DX
FEB 15, 2020
FDA nod for AI-powered technology to detect strokes
The US Food and Drug Administration (FDA) has provided clearance for a novel technology that uses artificial intelligenc ...
MAR 28, 2020
Drug Discovery & Development
MAR 28, 2020
FDA Approves 5-Minute Coronavirus Test
In recent weeks, the US has struggled to supply enough tests to detect the coronavirus. Now, however, this may change th ...
APR 01, 2020
Cardiology
APR 01, 2020
Avoiding Caries in Children
Thankfully, children are free of many of the chronic diseases that plague older populations. That said, one of the most ...
APR 08, 2020
Technology
APR 08, 2020
Can Quantum Technology Diagnose Complicated Heart Conditions?
Currently, atrial fibrillation (AF) is a heart condition that is diagnosed using an electrocardiogram (ECG). However, di ...
APR 22, 2020
Clinical & Molecular DX
APR 22, 2020
Microneedle Skin Patch Collects Bodily Fluids for On-patch Diagnostic Testing
The collection of blood for diagnostic tests is common practice in clinical settings. However, technicians often need to ...
Loading Comments...